A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Catherine Vincent et al.|New England Journal of Medicine|2016Cited by 1.1k
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, Pol Boudes et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinomaFrancesca Bernuzzi, Pietro Invernizzi, Francesco Marabita et al.|Clinical & Experimental Immunology|2016Cited by 83
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Christopher L. Bowlus et al.|Journal of Hepatology|2020Cited by 10
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 studyGideon M. Hirschfield, DE Jones, Pol Boudes et al.|Journal of Hepatology|2018Cited by 5